Navigation Links
Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program
Date:3/6/2009

NEW YORK, March 6 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Laboratorios Almirall, S.A. today announced after consultation with the U.S. Food and Drug Administration (FDA), that additional clinical studies of aclidinium bromide for the treatment of chronic obstructive pulmonary disease (COPD) will be conducted to provide further support for the selected regimens, including higher and/or more frequent doses. This decision follows a meeting with the FDA to review the previously reported ACCLAIM/COPD I and II studies. The Companies originally anticipated filing a New Drug Application (NDA) in the fourth quarter of 2009 or the first quarter of 2010, pending FDA feedback. Timelines for the development of the additional clinical studies and the future filing date of an NDA, including the ACCLAIM studies, are being determined.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

About COPD

The World Health Organization (WHO) has described COPD as a global epidemic; an estimated 210 million people have COPD worldwide and more than 3 million people died of the condition in 2005, which is equal to 5% of all deaths globally that year. Total deaths from COPD are projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly exposure to tobacco smoke.

The most common symptoms of COPD are breathlessness (or a "need for air"), abnormal sputum (a mix of saliva and mucus in the airway), and a chronic cough. Daily activities, such as walking up a short flight of stairs or carrying a suitcase, can become very difficult as the condition gradually worsens(1). There are significant unmet needs in the treatment of COPD including limited therapeutic
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
2. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
3. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
4. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
5. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
8. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
9. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
10. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
11. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Calif. , Sept. 1, 2015 ... Care Management (CCM) and Drug Adherence m Health ... help automate the process of non face-to-face monitoring ... "With this new release of our apps, doctors ... management services along with our ONCHIT certified Physician, ...
(Date:9/1/2015)... September 1, 2015 The ... the basis of sectors, products & services and ... coupled with the increasing demand of advanced drugs ... to propel the growth for bioinformatics market. The ... efficiently is known as bioinformatics. Decreasing cost of ...
(Date:9/1/2015)... -- In nur zwei Jahren nach dem Erreichen ... Group schnell weltweit 3.000 Mitarbeiter erreicht. Diese Steigerung ... Markt der injizierbaren Medikamente und das ... SHL wieder. Foto - http://photos.prnewswire.com/prnh/20150820/259886 ... Design und Herstellung automatischer Injektoren und Pen-Injektoren und ...
Breaking Medicine Technology:SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4SHL Group erreicht wichtigen Markstein von 3.000 Mitarbeitern 2
... 11, 2011 As part of its re-branding initiative, ... website www.xeridiem.com .  Winner of MD+DI,s 2011 Medical ... Supplies Xeridiem has been recognized as an industry leader ... invasive medical devices. For over 25 years, Xeridiem has ...
... Inc. (OTC: HEWA), a leading VIPPS-accredited, retail, mail-order ... have among the lowest total prices for four ... The study was conducted by 43,739 Consumer ... and speed.  "Our national study of prices for ...
Cached Medicine Technology:Consumer Reports Finds HealthWarehouse.com Has Lowest Total Price for Lipitor, Nexium, Plavix, and Singulair 2
(Date:9/1/2015)... Melbourne, Florida (PRWEB) , ... ... ... Association of Professional Background Screeners (NAPBS®) has announced that Edge Information ... audit conducted by the Background Screening Credentialing Council (BSCC). , “Achieving ...
(Date:9/1/2015)... Winston-Salem, NC (PRWEB) , ... September 01, 2015 , ... ... (Science, Technology, Engineering and Math) disciplines since its inception more than 35 years ago. ... and high-school students and their teachers - and, not just those intent on pursuing ...
(Date:9/1/2015)... ... ... Royal River Natural Foods, a locally-owned independent natural health store in Freeport, Maine, ... found that, among those who had a stroke, people who used multivitamins survived longer ... September 2015 issue of “Natural Insights for Well Being,” which Royal River Natural Foods ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... The ... and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of a collection ... same mission – to raise awareness of the FSH Society and further FSHD research. ...
(Date:9/1/2015)... ... , ... SC&H Group, a leading audit, tax, and consulting firm, received multiple ... Best” firm in the U.S., as well as being ranked a Top 100 Accounting ... U.S., selected exclusively on performance in specific areas of financial and operational management. ...
Breaking Medicine News(10 mins):Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2
... (TORONTO Nov. 28, 2011) A second, larger clinical ... Hospital (PMH) has again proven that comparing a new biopsy ... cancer can dictate a change in treatment. The ... Journal of Clinical Oncology . Principal investigator Dr. ...
... areas in the brain,s left hemisphere enable us to understand ... those areas divvy up the highly complex processes necessary to ... within the last 10 years have revealed that highly complex ... particular regions of the cerebral cortex, but also on the ...
... MONDAY, Nov. 28 (HealthDay News) -- Most U.S. heart ... hospital for a procedure to open narrowed or blocked ... 30 minutes or less, new research shows. The ... procedures such as balloon angioplasty or stent placement (called ...
... Academic institutions in Sweden are among the quickest to adopt ... Experiments ( JoVE ), with over 35 percent of ... for this phenomenon is that Swedes are among the fastest ... think we are a very curious people and interested in ...
... between breakfast and lunch lose less weight compared to those ... led by researchers at Fred Hutchinson Cancer Research Center., The ... Ph.D., a member of the Hutchinson Center,s Public Health Sciences ... in the December issue of the Journal of the ...
... a second primary cancer of the same type, according to ... Association Journal ) (pre-embargo link only) http://www.cmaj.ca/site/embargo/cmaj110167.pdf , whereas ... was only slightly elevated. Danish researchers looked at data ... people) from 1980 to 2007 to determine whether the risk ...
Cached Medicine News:Health News:New study shows biopsy of recurrent breast cancer can alter treatment 2Health News:How the brain strings words into sentences 2Health News:How the brain strings words into sentences 3Health News:How the brain strings words into sentences 4Health News:Lengthy Hospital Transfers May Hamper Heart Attack Care 2Health News:Swedish people are quick to adopt JoVE, a video journal for biomedical sciences 2Health News:Mid-morning snacking may sabotage weight-loss efforts 2Health News:Mid-morning snacking may sabotage weight-loss efforts 3Health News:Risk of second cancer in cancer survivors mainly confined to the same cancer type as the first 2Health News:Risk of second cancer in cancer survivors mainly confined to the same cancer type as the first 3
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: